Canada’s lagging healthcare productivity: Lost efficiencies and missed economic opportunities.
The solution to the sustainability challenge in healthcare is productivity gains – not rationing access to medical goods and services. Read More »
Private health insurance costs in Canada
Testing the insurance industry’s claims about the sustainability of drug plans. Read More »
Private versus public drug coverage in Canada
Experience shows competition and choice are better than government-run Pharmacare. Read More »
Challenging drug safety alarmism with facts
The facts do not support alarmist claims about the drug safety evaluation and surveillance system in Canada. Read More »
Facts about the cost of patented drugs in Canada
The cost of patented drugs is often cited to justify the regulation of pharmaceutical markets and to restrict public and private insurance coverage of new medicines. What are the facts about the cost of patented drugs in Canada? Read More »
Adverse drug reactions in Canada: facts v. urban myths
Alarmist claims about fatal drug reactions: are they supported by the facts? Read More »
Comparing access to new medicines by therapeutic class in public and private sector plans in Canada.
How good is your drug insurance coverage for the medicines that are most important to you? Read More »
Medical devices and healthcare costs in Canada and 65 other countries 2006-2011
What is the impact of medical device spending on total healthcare costs in Canada? How does Canada compare to other countries? Read More »
Does the increase in safety warnings from regulators actually mean that more dangerous drugs are being approved?
No link between faster drug approvals, regulatory safety warnings and drug withdrawals in Canada and the USA. Read More »
How good is your drug insurance?
How good is your drug insurance coverage? It depends on where you live and whether you are publicly or privately insured... Read More »
Potential costs from therapeutic substitution of proton pump inhibitor (PPI) drugs in Quebec
Lessons for Quebec from BC's experience with therapeutic substitution for PPI drugs? Read More »
Les coûts potentiels découlant de la substitution thérapeutique des médicaments de la classe des inhibiteurs de la pompe à protons (IPP) au Québec
Leçons pour le Québec de l'expérience de la Colombie-Britannique avec la substitution thérapeutique pour les médicaments IPP? Read More »